Letybo

Botulinum toxin type A, the active ingredient in Letybo, is a Botulinum toxin presented as an injectable for intramuscular use. It provides temporary muscle relaxation and is employed to manage spasticity, dystonia, migraine prevention and other neuromuscular conditions.

GNH USA supplies Letybo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Letybo, a botulinum toxin type A, acts on excessive muscle activity in several neurological and cosmetic indications.

- Spasticity: reduces muscle tone and improves functional mobility in patients with limb spasticity. - Cervical dystonia: alleviates abnormal neck muscle contractions and associated pain. - Blepharospasm: diminishes involuntary eyelid closure and improves visual function. - Chronic migraine prophylaxis: decreases frequency of migraine attacks in eligible adults. - Hyperhidrosis: reduces excessive sweating by blocking sympathetic nerve signals. - Cosmetic reduction of facial wrinkles: relaxes facial muscles to smooth dynamic lines.

Adverse reactions to Letybo are generally related to the injection site and the pharmacologic action of botulinum toxin.

Common Side Effects: - Injection site pain or tenderness. - Localized bruising or erythema. - Headache or flu‑like symptoms. - Transient weakness of adjacent muscles. - Dry mouth or mild dysphagia.

Serious or Rare Side Effects: - Dysphagia or respiratory compromise due to spread of toxin. - Allergic reactions including anaphylaxis. - Botulism‑like systemic effects such as generalized weakness. - Vision changes or ptosis. - Severe muscle weakness beyond the injection site.

Before using Letybo, consider the following precautions to ensure safe administration.

- Pregnancy: safety not established; avoid unless benefit outweighs risk. - Breastfeeding: unknown excretion; consider potential effects on the infant. - Neuromuscular disorders: use with caution as underlying weakness may be exacerbated. - Concomitant aminoglycosides or muscle relaxants: monitor for enhanced neuromuscular blockade. - Known hypersensitivity to botulinum toxin: contraindicated. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Letybo may interact with other medicines that affect neuromuscular transmission.

Major Interactions (Avoid): - Aminoglycoside antibiotics: may potentiate neuromuscular blockade. - Quinine: can increase risk of severe muscle weakness. - General anesthetics such as succinylcholine: heightened risk of respiratory compromise.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may reduce therapeutic efficacy. - Other botulinum toxin products: cumulative effect may increase toxicity. - Muscle relaxants (e.g., baclofen): may enhance local weakness.